10:39 AM
Courts uphold Merck's (MRK +1.7%) patent on its asthma drug, Singulair, dealing a blow to Teva Pharmaceutical (TEVA +0.8%), which had hoped to market a generic version before the patent expires in 2012. A generic would have blown a hole in Singulair's annual U.S. sales of $3B.
Comment!
Tuesday, July 28, 2009
07:00 AMTeva Pharmaceutical Industries (TEVA): Q2 EPS of $0.83 beats by $0.03. Revenue of $3.4B (+20%) vs. $3.5B. (PR)
Comment!
06:59 AM
Shares of Teva Pharmaceutical (TEVA) gain 1.1% in Tel Aviv after a phase-III trial of its Parkison's drug Azilect shows patients who began treatment immediately saw significant improvement compared to those who started treatment nine months later.
Comment!
Tuesday, July 29, 2008
06:53 AMTeva Pharmaceutical Industries (TEVA): Q2 EPS of $0.65 beats by $0.01. Revenue of $2.82B (+18.3%) vs. $2.68B. [PR]
Comment!